Back

Impact of cardiac magnetic resonance channels to localize deceleration zones during VT ablation

16 April 2023 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Ventricular Arrhythmias and SCD - Round 3 - Ablation Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2023

About the speaker

Photo
Doctor Sara Vazquez-Calvo

Hospital Clinic of Barcelona, Barcelona (Spain)

8 More presentations in this session

Presentation thumbnail
Reproducible target transfer from electroanatomic mapping to radiotherapy planning systems for cardiac radioablation - cross-validation for the RAVENTA trial
Doctor S. Hohmann (Hildesheim, DE)
Abstract Slides
Presentation thumbnail
Optimisation of decrementing evoked potential mapping for functional substrate identification in ischaemic ventricular tachycardia ablation
Doctor J. Al-Sheikhli (Coventry, GB)
Abstract Slides
Presentation thumbnail
Stereotactic Arrhythmia Radioablation (STAR) for refractory ventricular tachycardia (VT) - A preliminary report from the German multicenter RAVENTA study
Doctor S. Hohmann (Hildesheim, DE)
Abstract Slides
Presentation thumbnail
Sex differences in catheter ablation for ventricular tachycardia in structural heart disease: a single center 10-years experience.
Doctor N. Tanese (Milan, IT)
Abstract Slides
Presentation thumbnail
Impact of ventricular tachycardia ablation in S-ICD recipients: insights from the multicenter iSUSI registry
Doctor M. Schiavone (Milan, IT)
Abstract Slides

Access the full session

Session thumbnail
Ventricular Arrhythmias and SCD - Round 3 - Ablation

The Event

Event poster

EHRA 2023

16 April - 18 April 2023
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources